Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (ISRCTN10221007) titled 'A study to compare how the body takes in and gets rid of sefaxersen when given by an injection device or a regular syringe in healthy adults' on Sept. 10.
Study Type: Interventional
Study Design:
Interventional randomized parallel group controlled trial (Safety)
Primary Sponsor: F. Hoffmann-La Roche Ltd
Condition:
Healthy volunteers
Other
Intervention:
This is a Phase I, randomized, open-label, single-dose, parallel-group study in healthy male andfemale participants.
Participants will be randomized in a 1:1 ratio to receive a single SC dose of sefaxersen,
administered either via an injection device (Group ...